Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript

被引：0
|
作者：
A Tchirkov
J-L Couderc
B Périssel
C Goumy
A Regnier
N Uhrhammer
P Verrelle
M Berger
机构：
[1] Centre Jean Perrin,
[2] Service de Cytogénétique Médicale,undefined
[3] CHU – Faculté de Médecine,undefined
[4] UMR 384 INSERM,undefined
[5] Service de Médecine Interne,undefined
[6] CH,undefined
[7] Hématologie,undefined
[8] Faculté de Médecine,undefined
来源：
Leukemia | 2006年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：167 / 168
页数：1
相关论文
共 50 条
  • [21] Novel e8a2 BCR/ABL Fusion Transcript in Case of a Myeloproliferative Neoplasm
    Manoj Kumar Panigrahi
    Dushyant Kumar
    Anurag Mehta
    Moushumi Suryavanshi
    Dinesh Bhurani
    Kandarpa Kumar Saikia
    Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 271 - 272
  • [22] Novel e8a2 BCR/ABL Fusion Transcript in Case of a Myeloproliferative Neoplasm
    Panigrahi, Manoj Kumar
    Kumar, Dushyant
    Mehta, Anurag
    Suryavanshi, Moushumi
    Bhurani, Dinesh
    Saikia, Kandarpa Kumar
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (02) : 271 - 272
  • [23] e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?
    Demehri, S
    Paschka, P
    Schultheis, B
    Lange, T
    Koizumi, T
    Sugimoto, T
    Branford, S
    Lim, LC
    Kegel, T
    Martinelli, G
    Hochhaus, A
    Drucker, BJ
    Deininger, MWN
    LEUKEMIA, 2005, 19 (04) : 681 - 684
  • [24] Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia
    Carella, Angelo Michele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (03) : 249 - 251
  • [25] e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
    Colla, S
    Sammarelli, G
    Voltolini, S
    Crugnola, M
    Sebastio, P
    Giuliani, N
    HAEMATOLOGICA, 2004, 89 (05) : 611 - 613
  • [26] Poor response to imatinib therapy in chronic myeloid leukaemia expressing variant BCR-ABL transcripts
    Dutt, T.
    Lucas, C. M.
    Wang, L.
    Clark, R. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 66 - 66
  • [27] The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia
    Wang, LH
    Knight, K
    Lucas, C
    Clark, RE
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 235 - 239
  • [28] A Novel e8a2BCR-ABL1 Fusion Transcript without Insertion Sequence in a Patient with Chronic Myeloid Leukemia
    Jin, Caibao
    Zhu, Xiaojian
    Xiao, Min
    Liu, Songya
    Liu, Xian
    Liu, Jingjing
    Xu, Xiuwen
    Yi, Shujuan
    Meng, Li
    ANNALS OF LABORATORY MEDICINE, 2018, 38 (02) : 169 - 171
  • [29] A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript
    Li, Xiaoqing
    Yang, Jing
    Chen, Xiangjun
    Liu, Jun
    Li, Hongrui
    Zheng, Jine
    He, Yanli
    Chen, Zhong
    Huang, Shiang
    CANCER GENETICS AND CYTOGENETICS, 2007, 176 (02) : 166 - 168
  • [30] Evaluation of BCR-ABL/ABL Ratio Increase That Corresponds to BCR-ABL Mutation In Chronic Myeloid Leukemia Patients Treated by Imatinib
    Tsaur, Grigory
    Ivanova, Anna
    Popov, Alexander
    Yakovleva, Yulia
    Riger, Tatyana
    Plekhanova, Olga
    Ivanets, Yulia
    Misyurin, Andrey
    Suchkova, Marina
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    BLOOD, 2010, 116 (21) : 1402 - 1402
12345